FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Erasca's Trailing 12-Month Free Cash Flow is $-131.98 Mil, and Market Cap is $419.23 Mil. Therefore, Erasca's FCF Yield % for today is -31.48%.
The historical rank and industry rank for Erasca's FCF Yield % or its related term are showing as below:
ERAS'
s FCF Yield % Range Over the Past 10 Years
Min: -53.88 Med: 0 Max: 0
Current: -31.48
ERAS's FCF Yield % is ranked worse than 66.56% of 1501
companies
in the Biotechnology industry
Industry Median: -14.49
vs ERAS: -31.48
Erasca's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.
Erasca FCF Yield % Historical Data
The historical data trend for Erasca's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Erasca's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erasca's FCF Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Erasca's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Erasca's FCF Yield % falls into.
Erasca FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Erasca's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Erasca FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Erasca FCF Yield % Related Terms
Thank you for viewing the detailed overview of Erasca's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERAS has been successfully added to your 